Lista de obras -

90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease

artículo científico publicado en 2014

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

artículo científico publicado en 2004

A novel proteoliposomal vaccine elicits potent antitumor immunity in mice

artículo científico publicado en 2007

A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma

artículo científico publicado en 2007

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

scientific article published on 09 May 2019

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma

artículo científico publicado en 2011

Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion

artículo científico publicado en 2004

American Journal of Blood Research: Editorial Board (2011) e-Century Publishing Corporation

artículo científico publicado en 2011

Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy

artículo científico publicado en 2015

Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells

artículo científico publicado en 2006

Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes

artículo científico publicado en 2004

B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis

artículo científico publicado en 2005

Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression

artículo científico publicado en 2013

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies

scientific article published on 01 September 2019

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

artículo científico publicado en 2015

Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities

artículo científico publicado en 2012

Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo

artículo científico publicado en 2004

Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera

artículo científico publicado en 2006

Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach

artículo científico publicado en 2015

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

artículo científico publicado en 2014

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

artículo científico publicado en 2008

Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma

artículo científico publicado en 2015

Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice

artículo científico publicado en 2014

Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines ⬇️

artículo científico publicado el 23 de noviembre de 2010

Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis

artículo científico publicado en 2004

Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis

artículo científico publicado en 2007

Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.

artículo científico publicado en 2002

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial

artículo científico publicado en 2015

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma

artículo científico publicado en 2014

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

artículo científico publicado en 2012

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma

scientific article published on 28 February 2019

MACOP-B ± radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford Results According to Prognostic Indices ⬇️

artículo científico publicado el 15 de junio de 1993

Mammalian defensins in immunity: more than just microbicidal

artículo científico publicado en 2002

MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response

artículo científico publicado en 2011

Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone

artículo científico publicado en 2011

Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma

artículo científico publicado en 2013

Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells

artículo científico publicado en 2006

Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry

artículo científico publicado en 2004

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial

artículo científico publicado en 2014

Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.

artículo científico publicado en 2015

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

artículo científico publicado en 2012

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

artículo científico publicado en 2018

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

artículo científico publicado en 2008

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

artículo científico publicado en 2012

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes

artículo científico publicado en 2012

Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma

scientific article published on 26 April 2011

Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma

artículo científico publicado en 2013

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma ⬇️

artículo científico publicado el 5 de agosto de 2010

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

artículo científico publicado en 2015

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

artículo científico publicado en 2015

Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.

artículo científico publicado en 2007

Prime-boost vaccination using chemokine-fused gp120 DNA and HIV envelope peptides activates both immediate and long-term memory cellular responses in rhesus macaques

artículo científico publicado en 2010

Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.

artículo científico publicado en 2011

Prospective isolation of clonogenic mantle cell lymphoma-initiating cells

artículo científico publicado en 2010

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

artículo científico publicado en 2013

Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center

artículo científico publicado en 2015

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

artículo científico publicado en 2013

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

artículo científico publicado en 2014

Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma

artículo científico publicado en 2014

Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray

artículo científico publicado en 2004

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas

artículo científico publicado en 2012

Targeting cell surface β2 -microglobulin by pentameric IgM antibodies

artículo científico publicado en 2011

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

artículo científico publicado en 2014

Therapeutic idiotype vaccines in B lymphoproliferative diseases

artículo científico publicado en 2004

Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2.

artículo científico publicado en 2002

Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes

artículo científico publicado en 2014

Translational development of active immunotherapy for hematologic malignancies

artículo científico publicado en 2002

Vaccination strategies for lymphomas

artículo científico publicado en 2003

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma

artículo científico publicado en 2011

Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial

artículo científico publicado en 2012

Lista de obras de

90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

A novel proteoliposomal vaccine elicits potent antitumor immunity in mice

A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma

Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion

American Journal of Blood Research: Editorial Board (2011) e-Century Publishing Corporation

Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy

Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells

Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes

B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis

Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities

Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo

Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera

Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma

Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice

Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines ⬇️

Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis

Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis

Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma

MACOP-B ± radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford Results According to Prognostic Indices ⬇️

Mammalian defensins in immunity: more than just microbicidal

MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response

Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone

Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma

Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells

Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial

Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes

Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma

Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma ⬇️

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.

Prime-boost vaccination using chemokine-fused gp120 DNA and HIV envelope peptides activates both immediate and long-term memory cellular responses in rhesus macaques

Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.

Prospective isolation of clonogenic mantle cell lymphoma-initiating cells

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma

Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas

Targeting cell surface β2 -microglobulin by pentameric IgM antibodies

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

Therapeutic idiotype vaccines in B lymphoproliferative diseases

Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2.

Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes

Translational development of active immunotherapy for hematologic malignancies

Vaccination strategies for lymphomas

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma

Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial